LXRX

Lexicon Pharmaceuticals, Inc.

2.53 USD
+0.02 (+0.60%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lexicon Pharmaceuticals, Inc. stock is up 57.81% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 23 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 10 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
01 Feb 14:41 19 Apr, 2024 2.00 CALL 3038 12019
02 Feb 15:18 19 Jul, 2024 2.50 CALL 2400 1876
05 Feb 14:46 19 Apr, 2024 2.00 CALL 1223 11468
05 Feb 14:47 19 Apr, 2024 2.00 CALL 3777 11468
07 Feb 14:34 19 Jul, 2024 2.50 CALL 2398 4550
12 Feb 18:35 19 Apr, 2024 3.00 CALL 5944 640
12 Feb 18:35 19 Apr, 2024 3.00 CALL 1500 640
12 Feb 18:35 19 Apr, 2024 3.00 CALL 2556 640
13 Feb 20:43 19 Apr, 2024 3.00 CALL 4926 10324
15 Feb 15:10 19 Apr, 2024 3.50 CALL 4999 250

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the. treatment of neuropathic pain.